logo
This Incredibly Cheap Artificial Intelligence (AI) Stock Could Jump 8% as per Wall Street Analysts, But Don't Be Surprised to See It Soar Higher

This Incredibly Cheap Artificial Intelligence (AI) Stock Could Jump 8% as per Wall Street Analysts, But Don't Be Surprised to See It Soar Higher

Yahoo15-05-2025
The rapidly growing demand for high-speed data transmission is turning out to be a tailwind for this optical components supplier.
The company delivered impressive growth in its revenue and earnings last quarter, and the trend is expected to continue.
The robust growth in this tech stock's earnings and its cheap valuation are reasons why investors should consider buying it right away.
10 stocks we like better than Lumentum ›
Lumentum Holdings (NASDAQ: LITE) stock took a beating so far in 2025. That's not surprising, considering the broader weakness in the stock market on account of macroeconomic headwinds caused by the tariff-fueled trade war.
However, the 9% drop in Lumentum stock this year doesn't seem justified if we consider that artificial intelligence (AI) has been driving a solid turnaround in the company's business. Lumentum is known for selling optical and photonics components that enable high-speed data transmission in communications networks and data centers, and the demand for its products has taken off thanks to AI.
This explains why the company's growth has been picking up in recent quarters. In the latest fiscal 2025 third-quarter earnings report (for the three months ended March 29), which was released on May 6, Lumentum easily beat expectations.
Let's see what's driving Lumentum's growth, and why it may be a good idea to buy this tech stock hand over fist right now.
Lumentum's fiscal Q3 revenue increased 16% year over year to $425 million, while its non-GAAP net income nearly doubled year over year to $0.57 per share. The company's cloud and networking business played a key role in driving this solid growth as it accounted for 86% of the company's top line. Lumentum's non-GAAP operating margin shot up to almost 11% from a slightly negative reading in the year-ago period, which explains the big jump in its bottom line.
Lumentum credits the big jump in its margins and earnings to an improvement in manufacturing utilization rates and a favorable product mix. The company is expecting its gross margin to improve on a sequential basis in the current quarter as well, despite an estimated negative effect of 100 basis points on account of tariffs.
Additionally, Lumentum says that "AI-driven cloud growth will continue to drive our financial momentum into Q4 and beyond" despite the macroeconomic headwinds caused by the tariff turmoil. That's not surprising, as demand for Lumentum's externally modulated lasers (EML), which are used in optical communications because of their ability to enable high-speed data transmission with high efficiency, increased because of AI.
Lumentum's EML shipments hit a record last quarter, and the company believes that it can double revenue from this product this year compared to June 2024 levels. Moreover, the company is increasing its manufacturing capacity of EMLs to support the strong demand for these components. Such a move could pay off in the long run, since sales of optical components used in AI clusters are expected to double from $5 billion last year to $10 billion next year.
As such, Lumentum is forecasting a significant acceleration in revenue. The company guided for revenue of $455 million in the current quarter at the midpoint of its guidance range, which would translate into a year-over-year increase of 48%. It's expecting non-GAAP earnings per share to land between $0.70 to $0.80 per share, which points toward a significant multiplication over the year-ago period's figure of $0.06 per share.
Lumentum carries a 12-month median price target of $82, as per 18 analysts covering the stock. That points toward an 8% jump from current levels. However, a sharp spike in Lumentum's earnings growth could eventually translate into much stronger gains. Analysts project an 88% increase in Lumentum's earnings for fiscal 2025 to $1.90 per share. The forecast for the next fiscal year is even stronger, followed by another impressive jump in fiscal 2027.
Assuming Lumentum manages to achieve $4.77 per share in earnings in fiscal 2027 and trades at 25 times earnings at that time (in line with the tech-laden Nasdaq-100 index's forward earnings multiple), its stock price could hit $120 in a couple of years. That points toward potential gains of 58% from current levels.
Given that Lumentum is trading at just 19 times forward earnings, investors can buy this AI stock at an attractive valuation right now before it takes off in the long run.
Before you buy stock in Lumentum, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Lumentum wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $613,951!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $796,353!*
Now, it's worth noting Stock Advisor's total average return is 948% — a market-crushing outperformance compared to 170% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of May 12, 2025
Harsh Chauhan has no position in any of the stocks mentioned. The Motley Fool recommends Lumentum. The Motley Fool has a disclosure policy.
This Incredibly Cheap Artificial Intelligence (AI) Stock Could Jump 8% as per Wall Street Analysts, But Don't Be Surprised to See It Soar Higher was originally published by The Motley Fool
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

First Solar Stock Jumps After Q2 Beat and Raised Full-Year Outlook
First Solar Stock Jumps After Q2 Beat and Raised Full-Year Outlook

Yahoo

time21 minutes ago

  • Yahoo

First Solar Stock Jumps After Q2 Beat and Raised Full-Year Outlook

Aug 1 - First Solar (NASDAQ:FSLR) gained 6.5% on Friday afternoon after posting second?quarter results that topped Wall Street expectations and prompted the solar manufacturer to raise its full?year guidance. Warning! GuruFocus has detected 5 Warning Signs with FSLR. The company reported Q2 net income of $341.9 million, or $3.18 per share, compared with $349.4 million, or $3.25 per share, a year ago. Analysts surveyed by FactSet expected $2.66 per share. Revenue climbed to $1.1 billion from $1.01 billion a year earlier, driven by higher sales of solar modules to third?party customers. Management now projects 2025 revenue between $4.9 billion and $5.7 billion, up from a prior $4.5 billion to $5.5 billion. Earnings guidance tightened to $13.50$16.50 per share, versus the earlier $12.50$17.50 range. First Solar also raised the lower end of its full?year solar module shipment target to 16.719.3 GW and adjusted its gross margin outlook to $2.05$2.35 billion. CEO Mark Widmar said the company benefits from President Trump's recently enacted tax law, which favors U.S.?made solar panels while limiting credits tied to Chinese supply chains. Analysts note that ongoing trade and tariff uncertainty still poses challenges but may also create opportunities for domestic manufacturers. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Moderna Cuts Forecast, Stock Wobbles Despite Beat
Moderna Cuts Forecast, Stock Wobbles Despite Beat

Yahoo

time21 minutes ago

  • Yahoo

Moderna Cuts Forecast, Stock Wobbles Despite Beat

Moderna's (NASDAQ:MRNA) quarter was okay on the numbers, but the stock slid because the company pulled back its full-year revenue outlook after delaying some U.K. vaccine shipments into early 2026. Q2 revenue was $142Million, down 41% from a year ago, with COVID shot sales at $114Million and its RSV vaccine barely registering. That pushed the 2025 revenue range to $1.5Billion$2.2Billion, about $300Million less than before. Warning! GuruFocus has detected 2 Warning Sign with MRNA. The good part is they've been cutting costs aggressively. OpEx is now guided to $5.9Billion$6.1Billion roughly $400Million lighter than prior expectationsand that helped trim the loss to about $800Million. Moderna still has a strong cash cushion: $7.5Billion at the end of June and roughly $6Billion expected at year-end, so the balance sheet isn't stressed. The delayed shipments rattled sentiment, but the company isn't burning cash. Now it comes down to executionU.K. deliveries must land as rescheduled and new revenue drivers need to show up before investors lose patience. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Business Wire

time22 minutes ago

  • Business Wire

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last patient, last visit in its ongoing Phase 2 clinical trial (NCT05561751) evaluating the safety and efficacy of GPC-100 (burixafor) in combination with propranolol and G-CSF in multiple myeloma patients undergoing autologous stem cell transplant (ASCT). Topline results from the study are expected in the fourth quarter of 2025. The randomized, open-label, multicenter study is designed to assess whether GPC-100, a small molecule CXCR4 antagonist, can improve CD34+ hematopoietic stem cell mobilization from the bone marrow into the peripheral blood, where they can be collected via leukapheresis for use in ASCT. In data presented at ASH 2024, GPC-100 appears to be well differentiated in terms of the speed with which it mobilizes stem cells compared to currently approved stem cell mobilization treatments. Dr. Muthalagu Ramanathan, Director of the Myeloma Program and Medical Co-Director of the Blood and Marrow Transplant and CAR-T Program at U Mass Memorial Health noted that 'traditionally, patients undergoing mobilization are required to come, as an outpatient, the night before their procedure to receive the mobilization injection — a process that adds logistical challenges. The study drug GPC100 needed to be administered just 45 minutes before stem cell collection and resulted in a successful mobilization, significantly improving the patient experience. This is a true blessing for our frail myeloma patients.' In addition to multiple myeloma and a planned Phase 1 study in acute myeloid leukemia (AML) patients, the company is also in discussions for potential collaborations that would utilize GPC-100's rapid and safe mobilization of stem cells in cell and gene therapy settings. About GPC-100 GPC-100 (burixafor) is a highly selective small molecule antagonist of CXCR4, a chemokine receptor that plays a central role in retaining hematopoietic stem cells in the bone marrow niche. By blocking CXCR4, GPC-100 may enhance the mobilization of these cells into the peripheral blood for collection and use in autologous stem cell transplant (ASCT) procedures. Originally developed by GPCR Therapeutics, Inc., GPC-100 became part of Exicure's pipeline following the company's acquisition in January 2025. In addition to multiple myeloma, GPC-100 is also being considered in acute myeloid leukemia (AML) and other diseases where improved stem cell mobilization could help enable more efficient and effective treatment approaches, such as sickle cell disease, rare diseases requiring autologous transplant, and cell and gene therapy settings. About Exicure Exicure, Inc. (Nasdaq: XCUR) is a clinical-stage biotechnology company developing therapies to address key challenges in hematologic diseases. The company's lead program, GPC-100, is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. It is also being studied as a potential chemosensitizing agent in acute myeloid leukemia (AML). For more information, visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store